15 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2029. from the record
Of the 4 now held by other companies, 4 name Visus Therapeutics Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
May 2029
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2031 · High confidence
Also notable
Ends Dec 2040 · High confidence
In Situ Lysis of Cells in Lateral Flow Immunoassays
US 8,614,101
The most cited patent in this portfolio, cited by 105 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2031.
Selective White Blood Cell Lysis for Immunoassay Systems
US 12,078,636
Granted 2024. Too new for citation comparison; protection runs to 2040.
Formerly held, still cited
Notable
Ends Jul 2030 · High confidence
The largest patent family in this portfolio, 6 related applications, renewed at every maintenance window due so far. Protection runs to 2030.
now held by Visus Therapeutics, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Method and Device for Combined Detection of Viral and Bacterial Infections (US 10,379,121) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 2 fees due Mar 1 to 10, 2027 · next Mar 1
Recent changes
- 2 terms have ended since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Combined Visual/Fluorescence Analyte Detection Test | 14 in force | to Apr 2033 |
| Selective White Blood Cell Lysis for Immunoassay Systems | 1 in force | to Dec 2040 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,962,260 | Method and Device for Combined Detection of Viral and Bacterial Infections In force · High confidence | In force | High confidence | |
| US 9,372,192 | Method And Device For Combined Detection Of Viral And Bacterial Infections In force · Medium confidence | In force | Medium confidence | |
| US 10,808,287 | Improved Methods and Devices for Accurate Diagnosis of Infections In force · High confidence | In force | High confidence | |
| US 9,121,849 | Lateral Flow Assays In force · High confidence | In force | High confidence | |
| US 9,804,155 | Methods and Devices for Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) In force · High confidence | In force | High confidence | |
| US 9,933,423 | Method and Device for Combined Detection of Viral and Bacterial Infections In force · High confidence | In force | High confidence | |
| US 10,379,121 | Method and Device for Combined Detection of Viral and Bacterial Infections In force · High confidence | In force | High confidence | |
| US 10,408,835 | Method and Device for Combined Detection of Viral and Bacterial Infections In force · High confidence | In force | High confidence | |
| US 9,910,036 | Method and Device For Combined Detection Of Viral And Bacterial Infections In force · High confidence | In force | High confidence | |
| US 11,002,734 | Methods and Devices for Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 4 patents in force now held by others · 12 patents ended · 3 applications pending · 21 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed